PL3223796T3 - Kompozycje farmaceutyczne, ich wytwarzanie i zastosowania - Google Patents

Kompozycje farmaceutyczne, ich wytwarzanie i zastosowania

Info

Publication number
PL3223796T3
PL3223796T3 PL15800774T PL15800774T PL3223796T3 PL 3223796 T3 PL3223796 T3 PL 3223796T3 PL 15800774 T PL15800774 T PL 15800774T PL 15800774 T PL15800774 T PL 15800774T PL 3223796 T3 PL3223796 T3 PL 3223796T3
Authority
PL
Poland
Prior art keywords
preparation
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
PL15800774T
Other languages
English (en)
Inventor
Agnès Pottier
Matthieu Germain
Laurence Poul
Marion PAOLINI
Marie-Edith MEYRE
Original Assignee
Curadigm Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curadigm Sas filed Critical Curadigm Sas
Publication of PL3223796T3 publication Critical patent/PL3223796T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL15800774T 2014-11-25 2015-11-24 Kompozycje farmaceutyczne, ich wytwarzanie i zastosowania PL3223796T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14306876 2014-11-25
EP15800774.0A EP3223796B1 (en) 2014-11-25 2015-11-24 Pharmaceutical compositions, preparation and uses thereof
PCT/EP2015/077441 WO2016083338A1 (en) 2014-11-25 2015-11-24 Pharmaceutical compositions, preparation and uses thereof

Publications (1)

Publication Number Publication Date
PL3223796T3 true PL3223796T3 (pl) 2021-12-20

Family

ID=52013983

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15800774T PL3223796T3 (pl) 2014-11-25 2015-11-24 Kompozycje farmaceutyczne, ich wytwarzanie i zastosowania

Country Status (12)

Country Link
US (1) US11304902B2 (pl)
EP (1) EP3223796B1 (pl)
JP (1) JP6835733B2 (pl)
AR (1) AR102780A1 (pl)
DK (1) DK3223796T3 (pl)
ES (1) ES2890662T3 (pl)
HU (1) HUE056175T2 (pl)
LT (1) LT3223796T (pl)
PL (1) PL3223796T3 (pl)
PT (1) PT3223796T (pl)
TW (1) TW201628610A (pl)
WO (1) WO2016083338A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116380C2 (uk) * 2013-05-30 2018-03-12 Нанобіотікс Посилення терапевтичної або профілактичної ефективності фармацевтичної сполуки
IL290114B2 (en) 2014-11-25 2025-03-01 Curadigm Sas Pharmaceutical preparations, preparation and uses thereof
PT3229843T (pt) 2014-11-25 2020-03-06 Curadigm Sas Composição farmacêutica, a sua preparação e as suas utilizações
PT3229776T (pt) 2014-11-25 2023-08-17 Curadigm Sas Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações
WO2016189125A1 (en) 2015-05-28 2016-12-01 Nanobiotix Nanoparticles for use as a therapeutic vaccine
US20220143011A1 (en) 2017-05-16 2022-05-12 Bow River LLC Methods of treatment with cyp3a4 substrate drugs
AU2017414697B2 (en) * 2017-05-16 2020-03-05 Bow River LLC Methods of treatment
US10857144B2 (en) 2017-05-16 2020-12-08 Bow River LLC Methods of treatment

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4280918A (en) 1980-03-10 1981-07-28 International Business Machines Corporation Magnetic particle dispersions
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
GB9509321D0 (en) * 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
AU4821697A (en) * 1996-10-18 1998-05-15 Wayne State University 6',7'-dihydroxybergamottin, a cytochrome p450 ihnibitor in grapefruit juice
JPH10120597A (ja) 1996-10-22 1998-05-12 Eiken Chem Co Ltd リンパ節高集積性コロイド粒子
US6509371B1 (en) * 1997-08-19 2003-01-21 Warner-Lambert Company Compositions containing Bergamottin for increasing the oral bioavailability of pharmaceutical agents
GB0002835D0 (en) 2000-02-09 2000-03-29 Melvin William T Drug resistance in cancer
US8178123B2 (en) * 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
US20050090732A1 (en) 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
CA2547024C (en) 2003-12-22 2013-12-17 Bracco Research Sa Gas-filled microvesicle assembly for contrast imaging
WO2005086639A2 (en) 2004-02-10 2005-09-22 Barnes-Jewish Hospital Improved efficacy and safety of targeted particulate agents with decoy systems
US20060264804A1 (en) 2005-04-07 2006-11-23 Yoram Karmon Device and kit for delivery of encapsulated substances and methods of use thereof
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
WO2007122956A1 (ja) 2006-03-24 2007-11-01 Toto Ltd. 酸化チタン複合体粒子、その分散液、およびそれらの製造方法
WO2007116954A2 (en) 2006-03-30 2007-10-18 Fujifilm Corporation Inorganic nanoparticle comprising an active substance immobilized on the surface and a polymer
EP2019665B1 (en) * 2006-05-04 2018-09-19 Reformpharm Pty Ltd Drug release from nanoparticle-coated capsules
BRPI0815613A2 (pt) 2007-08-21 2015-03-24 Alza Corp Composições lipossômicas para administração in vivo de compostos de ácido borônico.
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
WO2009081287A2 (en) 2007-12-21 2009-07-02 University Of Guelph Polysaccharide nanoparticles
US9403789B2 (en) 2008-02-21 2016-08-02 Sequoia Pharmaceuticals, Inc. Benzofuran-containing amino acid inhibitors of cytochrome P450
WO2009142754A1 (en) 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dendritic conjugates and methods of use
EP2130553A1 (en) 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
WO2010048623A2 (en) 2008-10-26 2010-04-29 Board Of Regents, The University Of Texas Systems Medical and imaging nanoclusters
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
US8470891B2 (en) * 2009-12-23 2013-06-25 International Business Machines Corporation Biodegradable block polymers for drug delivery, and methods related thereto
US8580312B2 (en) 2010-02-17 2013-11-12 National University Corporation Kobe University Radiation therapy agent
ES2580135T3 (es) 2010-03-26 2016-08-19 Abraxis Bioscience, Llc Métodos de tratamiento de carcinoma hepatocelular
GB201009455D0 (en) 2010-06-04 2010-07-21 King S College London Nanoparticles and their uses in molecular imaging
US9782342B2 (en) 2010-10-11 2017-10-10 Wichita State University Composite magnetic nanoparticle drug delivery system
MX346144B (es) * 2010-12-17 2017-03-09 Arrowhead Res Corp * Porcion activadora del modulador farmacocinetico del agregado de galactosa para arnsi.
US20140227343A1 (en) 2011-01-31 2014-08-14 Centre National De La Recherche Scientifique Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles
US9956175B2 (en) 2011-01-31 2018-05-01 Nanobiotix Nanoparticles delivery systems, preparation and uses thereof
WO2013059295A2 (en) 2011-10-17 2013-04-25 Trustees Of Boston University Polymeric depots for localization of an agent to biological sites
CN102532154B (zh) * 2012-01-11 2014-05-14 昆明医学院 隆萼当归线型呋喃香豆素化合物及其应用
WO2014039874A2 (en) 2012-09-07 2014-03-13 Carnegie Mellon University Methods and materials for reducing reticuloendothelial system clearance of particles from a subject
ITRM20120480A1 (it) 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
KR101378430B1 (ko) * 2012-11-05 2014-03-27 초당약품공업 주식회사 세스퀴터핀 락톤계 위장 질환 치료용 의약 조성물
US20140186447A1 (en) 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
UA116380C2 (uk) 2013-05-30 2018-03-12 Нанобіотікс Посилення терапевтичної або профілактичної ефективності фармацевтичної сполуки
EP2886128A1 (en) 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
PT3229776T (pt) 2014-11-25 2023-08-17 Curadigm Sas Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações
PT3229843T (pt) 2014-11-25 2020-03-06 Curadigm Sas Composição farmacêutica, a sua preparação e as suas utilizações
CA2968473A1 (en) 2014-11-25 2016-06-02 Nanobiotix Pharmaceutical composition, preparation and uses thereof
IL290114B2 (en) 2014-11-25 2025-03-01 Curadigm Sas Pharmaceutical preparations, preparation and uses thereof

Also Published As

Publication number Publication date
DK3223796T3 (da) 2021-09-27
AR102780A1 (es) 2017-03-22
EP3223796A1 (en) 2017-10-04
LT3223796T (lt) 2021-10-25
JP2017536419A (ja) 2017-12-07
ES2890662T3 (es) 2022-01-21
US20170258720A1 (en) 2017-09-14
HUE056175T2 (hu) 2022-01-28
JP6835733B2 (ja) 2021-02-24
US11304902B2 (en) 2022-04-19
TW201628610A (zh) 2016-08-16
PT3223796T (pt) 2021-09-28
WO2016083338A1 (en) 2016-06-02
EP3223796B1 (en) 2021-07-21

Similar Documents

Publication Publication Date Title
IL276695B (en) Antibodies, pharmaceutical preparations and their uses
ZA201605300B (en) Pharmaceutical compositions comprising azd9291
GB201419257D0 (en) Pharmaceutical compositions
GB201618482D0 (en) Pharmaceutical compositions
IL290114A (en) Pharmaceutical preparations, their preparation and uses
IL249553A0 (en) Pharmaceutical preparations
HUE056175T2 (hu) Gyógyászati készítmények, elõállításuk és alkalmazásaik
IL252397A0 (en) Pharmaceutical preparations, their preparation and uses
IL252897A0 (en) Indanyl compounds, pharmaceutical preparations and their medical uses
PT3200772T (pt) Composições farmacêuticas compreendendo alpelisib
PL3229843T3 (pl) Kompozycja farmaceutyczna, wytwarzanie i zastosowanie tej kompozycji
IL262929A (en) Preparations for treatment, methods for their preparation and their uses
IL250817A0 (en) pharmaceutical preparations
SG10202106375UA (en) Pharmaceutical compositions and use thereof
TH1501007100A (th) องค์ประกอบทางเภสัชกรรม, การเตรียม และการใช้ของมัน
GB201408432D0 (en) Pharmaceutical compositions